Speaking about MDUFA, Stephen J. Ubl of AdvaMed said, in the House-related release, “This potentially game-changing user fee agreement includes provisions that will strengthen accountability measures provide additional FDA resources. And under the agreement, the FDA is presented with an opportunity to improve its predictability, consistency and efficiency, while continuing to adhere to its high standard for product approval.”
With the two versions of the legislation now passed, Mr. Ubl spoke of AdvaMed’s desire to assist Congress in reconciling them so the agreement is passed “promptly.”
Related Articles on AdvaMed:
AdvaMed Commends Congress on Progress on Reauthorization of Medical Device User Fees
AdvaMed Unveils Three-Year Strategic Policy and Advocacy Plan
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.